Last reviewed · How we verify
NCT03384433
Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke
Phase 1, PHASE2 trial testing exosome in Cerebrovascular Disorders in 5 participants. Status unknown.
17 June 2021
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 17 April 2019 |
| Primary completion | 17 June 2021 |
| Estimated completion | 17 December 2021 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- exosome — full drug profile →
Conditions studied
- Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →
Sponsor
Isfahan University of Medical Sciences
Who can join
Adults 40 to 80, any sex, with Cerebrovascular Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Administration of cell-free exosomes derived from mesenchymal stem cell (MSCs) can be sufficient to exert therapeutic effects of intact MSCs after brain injury. In this study we aim to assay the administration of MSC derived exosome on improvement of disability of patients with acute ischemic stroke
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
RNA delivery by extracellular vesicles in mammalian cells and its applications.
O'Brien K, Breyne K, Ughetto S, Laurent LC, et al · · 2020 · cited 1306× · PMID 32457507 · DOI 10.1038/s41580-020-0251-y -
Advances in therapeutic applications of extracellular vesicles.
Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, et al · · 2019 · cited 791× · PMID 31092696 · DOI 10.1126/scitranslmed.aav8521 -
Extracellular vesicles as tools and targets in therapy for diseases.
Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, et al · · 2024 · cited 686× · PMID 38311623 · DOI 10.1038/s41392-024-01735-1 -
Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation.
Yang Z, Shi J, Xie J, Wang Y, et al · · 2020 · cited 551× · PMID 31844155 · DOI 10.1038/s41551-019-0485-1 -
Challenges and advances in clinical applications of mesenchymal stromal cells.
Zhou T, Yuan Z, Weng J, Pei D, et al · · 2021 · cited 489× · PMID 33579329 · DOI 10.1186/s13045-021-01037-x -
A review on exosomes application in clinical trials: perspective, questions, and challenges.
Rezaie J, Feghhi M, Etemadi T. · · 2022 · cited 460× · PMID 36123730 · DOI 10.1186/s12964-022-00959-4 -
Clinical applications of stem cell-derived exosomes.
Tan F, Li X, Wang Z, Li J, et al · · 2024 · cited 390× · PMID 38212307 · DOI 10.1038/s41392-023-01704-0 -
Exosome Processing and Characterization Approaches for Research and Technology Development.
Lai JJ, Chau ZL, Chen SY, Hill JJ, et al · · 2022 · cited 385× · PMID 35332686 · DOI 10.1002/advs.202103222
Verify or expand the search:
- PubMed search for NCT03384433
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of exosome
Trials testing the same drug.
- NCT06568653 — Human Placenta Mesenchymal Stem Cells Derived Exosomes Injection for Treatment of Complex Anal Fistula · Phase 2 · not yet recruiting
- NCT04127591 — Differential Expression and Analysis of Peripheral Plasma Exosome miRNA in Patients With Myocardial Infarction · unknown
Other recruiting trials for Cerebrovascular Disorders
Currently open trials in the same condition.
- NCT07185022 — Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
- NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting
- NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03384433 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 25 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03384433.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing